When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. By looking at an individual person’s epigenetics, the company can provide invaluable insight into the impact of their lifestyle, behavior, and environment—factors that traditional genetic testing often misses.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls gene expression, allowing the body to adapt to its surroundings. For example, stress, diet, exercise, and exposure to pollutants can all leave epigenetic marks that influence the risk of developing cardiovascular disease.
Cardio Diagnostics’ approach does more than pinpoint a problem, according to its CEO; it also provides some level of solution. By identifying specific epigenetic changes, clinicians can recommend targeted lifestyle interventions or therapies to potentially reverse or mitigate risk. This proactive strategy could shift the paradigm from reactive treatment to prevention.
The implications for patients and the healthcare industry are significant. Traditional risk assessments, such as cholesterol levels and family history, often fail to capture the full picture. Epigenetic testing could identify individuals at high risk who would otherwise be overlooked, enabling earlier and more personalized interventions. For the industry, it represents a move toward precision medicine, where treatments are tailored to an individual’s unique biological state.
For more information on Cardio Diagnostics and its technology, visit the company’s newsroom at https://ibn.fm/CDIO. As with any forward-looking statements, readers are encouraged to review the full terms of use and disclaimers available at http://IBN.fm/Disclaimer.
